ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TECH vs ABBV // GROSS PROFIT MARGIN

Bio-Techne Corp (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TECH 2 — ABBV 12
▲ GROSS PROFIT MARGIN LEADER: ABBV
gross-margins
64.80%
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TECH VS. ABBV) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TECH ABBV SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 64.80% 70.20% -5.40 ABBV /gross-margins <GO>
Return on Invested Capital (ROIC) 3.40% 29.00% -25.60 ABBV /roic <GO>
EV/EBITDA & P/E Valuation 91.3x 33.3x +58.00 ABBV /valuation <GO>
Free Cash Flow Yield 2.25% 3.47% -1.22 ABBV /fcf-yield <GO>
Operating Margin 8.40% 24.60% -16.20 ABBV /operating-margins <GO>
Net Profit Margin 6.00% 6.90% -0.90 ABBV /net-margins <GO>
Revenue Growth (YoY) 5.20% 8.60% -3.40 ABBV /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.44% 2.27% -1.83 ABBV /dividend-safety <GO>
Altman Z-Score & Debt/Equity 7.12 5.33 +1.79 TECH /balance-sheet <GO>
Piotroski F-Score Quality 8/9 7/9 +1.00 TECH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 59.3 65.1 -5.80 ABBV /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.88 1.15 -0.27 ABBV /macro-sensitivity <GO>
Forward P/E Multiple 140.0x 113.1x +26.90 ABBV /forward-pe <GO>
Enterprise Scale & Market Cap $11.40B $513.86B -$502.46B ABBV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TECH REV ABBV REV TECH GROSS % ABBV GROSS % TECH FCF ABBV FCF
FY 2025 $1.22B $61.16B 64.8% 70.2% $256.6M $17.82B
FY 2024 $1.16B $56.33B 66.4% 70.0% $236.1M $17.83B
FY 2023 $1.14B $54.32B — — $203.2M $20.39B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TECH // BETA 0.88
ABBV // BETA 1.15